2.0
29 Jan 2018
Current employee, more than 5 years
Parsippany, NJ
Recommend
CEO approval
Business outlook
Pros
Outstanding product, good potential but no value proposition for institutions if they don’t buy in to Opioid epidemic and cause.
Cons
It’s what you don’t read about.... CMO, VPMA, COO all recently departed or demoted, no real pipeline development to discuss, recent article debunks myth about Opioid misuse/abuse starts in operating room, not hitting revenue numbers for multitude of reasons. Poor management, high turnover and now another restructuring.